BamSEC and AlphaSense Join Forces
Learn More

Clearside Biomedical Inc.

NASDAQ: CLSD    
Share price (1/8/25): $0.97    
Market cap (1/8/25): $73.8 million

Material Contracts Filter

EX-10.2
from 10-Q 12 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Amendment 1 to the License Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Clearside Biomedical, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective March 14, 2024
12/34/56
EX-10.35
from 10-K 5 pages First Amendment to Consulting Agreement
12/34/56
EX-10.33
from 10-K 6 pages Fourth Amendment to the License Agreement
12/34/56
EX-10.31
from 10-K 62 pages License Agreement by and Between Biocryst Pharmaceuticals, Inc. and Clearside Biomedical, Inc. November 1, 2023
12/34/56
EX-10.2
from 8-K 9 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 4 pages Reference Is Hereby Made to (I) That Certain Purchase and Sale Agreement, Dated as of August 8, 2022 (As Amended to Date, the “Purchase Agreement”), by and Among Clearside Royalty LLC, a Delaware Limited Liability Company (“Seller”), Healthcare Royalty Partners IV, L.P. a Delaware Limited Partnership (“Purchaser”), and Hcr Clearside Spv, LLC (As Assignee of Hcr Collateral Management, LLC) (“Agent”, and Together With Seller and Purchaser, Each a “Party”, and Collectively, the “Parties”) and (II) That Certain Escrow Agreement, Dated as of August 8, 2022 (As Amended to Date, the “Escrow Agreement”) by and Among Seller, Agent and U.S. Bank National Association (“Escrow Agent”). Capitalized Terms Used Herein and Not Otherwise Defined Herein Shall Have the Meanings Given to Such Terms in the Purchase Agreement. This Letter Agreement (This “Letter Agreement”) Is Being Entered Into by and Among Purchaser, Seller and Agent to Confirm the Agreement Among the Parties as to Certain Matters Relating to the Purchase Agreement and the Escrow Agreement. Now, Therefore, for Good and Valuable Consideration, the Receipt and Sufficiency of Which Is Hereby Acknowledged, the Parties Hereto Hereby Agree as Follows: 1. First Milestone Payment. (A) Notwithstanding Anything to the Contrary in the Purchase Agreement, Seller Desires To, and Hereby Does, Waive Any and All Rights as to the First Milestone Payment. Purchaser and Agent Hereby Acknowledge and Accept Such Waiver
12/34/56
EX-10.1
from 8-K 42 pages Clearside Biomedical, Inc. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-10
from 10-K 6 pages Amendment No. 1 to the Option and License Agreement
12/34/56
EX-10
from 10-K 11 pages First Amendment to Office Lease Agreement
12/34/56
EX-10
from 8-K 12 pages Clearside Biomedical, Inc. Consulting Agreement Effective Date: February 17, 2023
12/34/56
EX-10.1
from 10-Q 64 pages Purchase and Sale Agreement Dated as of August 8, 2022 Between Clearside Royalty LLC and Healthcare Royalty Partners IV, L.P., and Hcr Collateral Management, LLC, Solely in Its Capacity as Agent for Purchaser
12/34/56
EX-10.1
from 10-Q 3 pages Clearside Biomedical, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective June 22, 2022
12/34/56
EX-10.14
from 10-K 3 pages Clearside Biomedical, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective June 18, 2020
12/34/56
EX-10.3
from 10-Q 4 pages Second Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 6 pages Amendment No. 2 to License Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Amendment No. 1 to License Agreement
12/34/56
EX-10.2
from 10-Q 12 pages Executive Employment Agreement
12/34/56